BTIG Maintains Buy on Haemonetics, Raises Price Target to $96

Benzinga Newsdesk www.benzinga.com Positive 80.6%

Neg 0% Neu 0% Pos 80.6%

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $84 to $96.

Comments

No comments yet. Be the first!